Production (Stage)
Entrada Therapeutics, Inc.
TRDA
$7.59
-$0.26-3.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -17.35M | 1.13M | -14.03M | 55.03M | 23.50M |
| Total Depreciation and Amortization | 946.00K | 992.00K | 937.00K | 910.00K | 934.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.75M | 2.19M | 1.65M | 2.36M | 1.70M |
| Change in Net Operating Assets | -25.85M | -35.92M | -12.82M | -18.47M | -51.65M |
| Cash from Operations | -38.51M | -31.61M | -24.27M | 39.83M | -25.52M |
| Capital Expenditure | -1.14M | -635.00K | -639.00K | -1.05M | -838.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 5.93M | 54.00M | -82.29M | -23.34M | 26.99M |
| Cash from Investing | 4.78M | 53.37M | -82.93M | -24.38M | 26.15M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 350.00K | 1.40M | -- | 101.37M | 206.00K |
| Repurchase of Common Stock | -- | -- | -11.00K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 350.00K | 1.40M | -11.00K | 101.37M | 206.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -33.37M | 23.16M | -107.20M | 116.82M | 834.00K |